Original Query: ALL
Previous Study | Return to List | Next Study

Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00455702
Recruitment Status : Completed
First Posted : April 4, 2007
Results First Posted : August 7, 2014
Last Update Posted : August 7, 2014
Information provided by (Responsible Party):
Donald C. Goff, MD, Massachusetts General Hospital

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Schizophrenia
Intervention: Drug: d-cycloserine

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were stable adult outpatients at an urban community mental health center, ages 18-65 years, with a diagnosis of schizophrenia .

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
D-cycloserine 50 mg d-cycloserine
Placebo 50 mg placebo

Participant Flow:   Overall Study
    D-cycloserine   Placebo
STARTED   19   19 
COMPLETED   16   16 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
D-cycloserine 50 mg d-cycloserine
Placebo 50 mg placebo
Total Total of all reporting groups

Baseline Measures
   D-cycloserine   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 19   19   38 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   19   19   38 
>=65 years   0   0   0 
[Units: Years]
Mean (Standard Deviation)
 50.1  (9.15)   48  (6.66)   49.05  (7.905) 
[Units: Participants]
Female   9   6   15 
Male   10   13   23 
Region of Enrollment 
[Units: Participants]
United States   19   19   38 

  Outcome Measures

1.  Primary:   Main Outcome Measure: The Change From Baseline to Week 8 on the SANS   [ Time Frame: Baseline score vs. Week 8 ]

2.  Secondary:   Treatment Effects on the Positive Syndrome Subscale of the PANSS   [ Time Frame: Baseline score vs. Week 8 score ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
As the first study of once-weekly dosing in Schizophrenia, this study was exploratory and so results must be considered preliminary. Additional studies are needed to replicate these findings.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Donald C Goff
Organization: Massachusetts General Hopsital
phone: 617-912-7899

Publications of Results:

Responsible Party: Donald C. Goff, MD, Massachusetts General Hospital Identifier: NCT00455702     History of Changes
Other Study ID Numbers: 2005-P-001040
First Submitted: April 2, 2007
First Posted: April 4, 2007
Results First Submitted: June 11, 2014
Results First Posted: August 7, 2014
Last Update Posted: August 7, 2014